IP Library Granted Patent US 8,163,533
Granted Patent B2
US 8,163,533 · App. 11/577,303 · Granted Apr 24, 2012

Methods and compositions for combinatorial-based production of multivalent recombinant antigens

Assignee: Intrexon Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,163,533
App. No.
11/577,303
Granted
Apr 24, 2012
Kind
B2
Abstract

The present invention provides methods and compositions for rapidly producing multivalent recombinant vaccines using filamentous fungal heterokaryons. The present invention relies on the use of filamentous fungal heterokaryons that are generated from combinations of two or more parent strains into which recombinant DNA molecules encoding variants of antigens derived from pathogenic organisms have been introduced. The resulting vaccines are multivalent.

Claims (4)

1. Filamentous fungal heterokaryons wherein said heterokaryons produce multivalent recombinant variants of antigens, said antigens comprise influenza type A and type B hemagglutinin and neuraminidase, said multivalent variants aggregate into particles that are secreted into the culture media, said heterokaryons are formed by fusing two or more fungal parent strains, said heterokaryons require the presence of all fungal parent nuclei for survival, said parent fungal strains each contains an exogenously supplied nucleic acid molecule that encodes a variant of said antigens, and said fungal parent strains are homozygous for all heterokaryon compatibility alleles.

2. The heterokaryons of claim 1 wherein each of said variants of influenza type A and type B hemagglutinin and neuraminidase is a naturally occurring variant.

3. The heterokaryons of claim 1 wherein each of said variants of influenza A and influenza B hemagglutinin and neuraminidase is not a naturally occurring variant.

4. A method to produce a multivalent vaccine, said method comprising the step of culturing the heterokaryons of claim 1 under conditions in which the exogenously supplied nucleic acid molecules are expressed so as to form a multivalent vaccine.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2012
From: BYTC CORPORATION
To: INTREXON CORPORATION
Reel/Frame 027688/0633 →
CHANGE OF NAME Recorded Feb 10, 2012
From: NEUGENESIS CORPORATION
To: BYTC CORPORATION
Reel/Frame 027689/0225 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2007
From: STUART, W. DORSEY; CAMBARERI, EDWARD B.
To: NEUGENESIS CORPORATION
Reel/Frame 020183/0425 →
Continuity (2)
Provisional Application 60619364 · Oct 15, 2004
Related Publication 20080318274A1 · Dec 25, 2008